Post by Pulmonary Hypertension Knowledge Sharing Platform

A recent study titled "Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: a Pulmonary Vascular Research Institute (PVRI) GoDeep Meta-Registry Analysis" reveals that in people with severe pulmonary hypertension with interstitial lung disease (PH-ILD), especially idiopathic pulmonary fibrosis, treatment with PDE5 inhibitors – and possibly in combination with other therapies – might improve survival. Authors say that further research is needed to confirm these findings, but these preliminary results are promising and could help guide future clinical trials. Read more on the Pulmonary Hypertension Knowledge Sharing Platform at this link https://lnkd.in/dPQe_nAu Authors: Athiththan Yogeswaran, Paul M Hassoun, Khaled Saleh, Meike Fünderich, Aparna Balasubramanian, Ziad Konswa, David G Kiely, Allen Lawrie, Thenappan Thenappan, Christina A Eichstaedt, Ekkehard Grünig, @Martin R Wilkins,Luke Howardd,Horst Olschewskii, Gabor Kovacs, Hector R Cajigas, Robert Frantz, Hani Sabbour, Andrew J Sweatt,Roham Zamaniann T Zamanian, Alexandra Arvanitaki,George Giannakoulass, Jean Elwing, Arun Jose, Stephan Beckmann, Karen M Olsson, Stefan Stadler, Matthias Held, Michael Halank, Ralf Ewert, Jürgen Behr, Katrin Milger-Kneidinger, Christine Pausch, David Pittrow, Raphael W Majeed, Jochen Wilhelm, Ardeschir Ghofranii, Friedrich Grimminger, Khodr Tello, Marius M Hoeper,Werner Seeger HTaPFrance Stichting Pulmonale Hypertensie / PH Association the Netherlands PH Belgium - Pulmonale Hypertensie vzw AIPI Associazione Ipertensione Polmonare Italiana - Italian Pulmonary Hypertension Association Pulmoner Hipertansiyon ve Skleroderma Hasta Dernegi Hellenic Community for Pulmonary Hypertension Pulmonale Hypertonie E.V. Ieva Plume PHA Polska PHA Japan Alliance for Pulmonary Hypertension